Journal of Medicinal Chemistry · 2012 · 14 citations · 8 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyNeuropharmacologyCholinergic NeurochemistryCholinergic PharmacologyNeurodegenerative Disease PharmacologyReceptor PharmacologySchizophrenia PharmacotherapyAcetylcholine Receptor PharmacologyAgonist ActivityAgonists Of Cholinergic ReceptorsCholinergic Receptor PharmacologyFull Agonist EfficacyNicotinic Acetylcholine Receptor AgonismNicotinic Receptor PharmacologyPlasma Stability Improvement
α7 Nicotinic acetylcholine receptors (α7 nAChR) represent promising therapeutic candidates for the treatment of cognitive impairment associated with Alzheimer's disease (AD) and schizophrenia. A medicinal chemistry effort around previously reported compound 1 (SEN15924, WAY-361789) led to the identification of 12 (SEN78702, WYE-308775) a potent and selective full agonist of the α7 nAChR that demonstrated improved plasma stability, brain levels, and efficacy in behavioral cognition models.
8
Philippe Séguéla, Jacques I. Wadiche, Kelly Dineley‐Miller et al. · Journal of Neuroscience · 1993 · 1.5K citations · Full text
Donn G. Wishka, Daniel P. Walker, Karen M. Yates et al. · Journal of Medicinal Chemistry · 2006 · 190 citations · Full text